期刊文献+

良性前列腺增生患者在社区医院的用药评估与宣教

Medical Therapy Evaluation and Education for BPH Patients in Community Hospital
下载PDF
导出
摘要 目的分析社区医院良性前列腺增生患者药物治疗所存在的问题,加强社区医师合理用药指导与宣教,以达到社区规范化治疗的目的。方法选择在我院门诊就诊的良性前列腺增生患者126例作为观察对象,对照实施社区医师对专科用药评估中不合理现象并进行指导干预前后患者的不合理用药例数、IPSS和生活质量指数变化情况。结果干预前不合理用药33例、占26.2%,干预后7例,占5.8%,两者比较经χ2检验,P<0.01,差异有统计学意义;干预前IPSS和生活质量指数分别是20.06±4.79、4.27±1.43,干预后分别为10.98±2.86、1.54±1.95,两者比较经t检验,P<0.05,差异有统计学意义。结论社区医院良性前列腺增生患者药物治疗存在不合理现象,应强化患者对药物治疗的认知水平,重视用药的合理性;通过加强社区医师对患者进行用药指导和宣教,提高药物治疗的合理性,降低IPSS评分和生活质量指数,达到社区规范化治疗的目的。 [Abstract] Objective To guide for medical therapy and standardized treatment by analyzing the problems in medical therapy for BPH Patients in community hospital. Methods 126 cases of BPH patients were chosen as Observation objects by comparing unreasonable phenomena in medicine evaluation and unreasonable medicine cases before and after intervention, IPSS and life quality index. Results The unreasonable medicine was statistically significant before and after intervention (33 cases, 26.2% vs 7 cases, 5.8%, P〈0.01); IPSS and life quality index had statistical significance before and after the intervention (20.06 ±4.79 vs 10.98 ± 2.86, 4.27± 1.43 vs 1.54 ± 1.95, P〈0.05). Conclusion The medical therapy for BPH patients in community hospital is unreasonabe. Patients should improve cognitive level for medical therapy and focus on medicine rationality. By guiding and educating patients for medical therapy, doctors improve the rationality of medical therapy, decrease IPSS evaluation and life quality index, thus reach the goal of standardized treatment in community hospital.
作者 张淳
出处 《临床医学工程》 2014年第3期384-385,共2页 Clinical Medicine & Engineering
关键词 良性前列腺增生 社区医院 用药评估 宣教 Benign prostatic hyperplasia Community hospital Medicine evaluation Education
  • 相关文献

参考文献8

  • 1Borth CS, Beiko DT, Nickel JC. Impact of medical therapy on transurethral resection of the prostate: a decade of change [J] . Urolo- gy, 2001, 57 (6) : 1082-1085. 被引量:1
  • 2Pinto F, Racioppi M, Sacco E, et al. Progression,risk factors and sub- sequent medical management of symptomatic benign prostatic hyper- plasia [J'] . Arch Ital Urol Androl, 2009, 81 (1) : 1-8. 被引量:1
  • 3张祥华,王行环,王刚,等.良性前列腺增生诊断治疗指南(2006年试行版)[C]//贵州省医学会泌尿外科分会2006年学术年会论文汇编,2006年,2006:146-166. 被引量:1
  • 4陈新谦,金有豫,汤光主编..新编药物学[M].北京:人民卫生出版社,2007:1004.
  • 5Kaplan SA, McConnell JD, Roehrbom CG, et al. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in pa- tients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater [J] . J Urol, 2006, 175 (1) : 217-220. 被引量:1
  • 6范治国,刘航.良性前列腺增生症的药物治疗与评价[J].中国医院用药评价与分析,2012,12(11):964-966. 被引量:4
  • 7杨勇.从循证医学证据理解良性前列腺增生的药物治疗[J].临床药物治疗杂志,2007,5(2):4-7. 被引量:4
  • 8沈昊,张玲,刘修恒,匡幼林.初诊良性前列腺增生症患者的循证治疗[J].职业与健康,2010,26(23):2876-2880. 被引量:1

二级参考文献50

  • 1孙颖浩,钱松溪,许传亮,马永江.Nd:YAG非接触式激光治疗前列腺增生(附32例报告)[J].中华泌尿外科杂志,1996,17(7):434-434. 被引量:8
  • 2潘沛,吕加国.α_(1A)-受体拮抗剂研究新进展[J].中国药学杂志,2006,41(20):1521-1524. 被引量:14
  • 3[1]Chute CG,Panser LA,Girman CJ,et al.The prevalence of prostatism:a population-based survey of urinary symptoms.J Urol,150:85-89,1993 被引量:1
  • 4[2]Barry MJ,Cockett ATK,Holtgrewe HL,et al.Relationship of symptoms of prostatism to commonly used physiologieal and anatomical measures of the severity of benign prostatic hyperplasia.J Urol,1993,150:351-358 被引量:1
  • 5[3]Mc Connell JD.Finateride therapy for benign prostatic hyperplasia.In:Kirby R,MeConnell JD,Fitzpatrick JM.,Roehrborn CG,Boyle P.editors.Textbook of Benign Prostatic Hyperplasia.Oxford:Isis Medical Media Ltd,1996:259-265 被引量:1
  • 6[4]Lepor H,Williford WO,Barry MJ,et al.The efficacy of terazosin,finasteride,or both in benign prostatic hyperplasia.Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.N Engl J Med.1996,335(8):533-539 被引量:1
  • 7[5]Mc Connell JD,Roehrborn CG,Bautista OM,et al.Medical Therapy of Prostatic Symptoms (MTOPS)Research Group.The longterm effect of doxazosin,finasteride,and combination therapy on the clinical progression of benign prostatic hyperplasia.N Engl J Med.2003,349(25):2387-2398 被引量:1
  • 8[6]Lepor H.Landmark studies impacting the medical management of benign prostatic hyperplasia.Rev Urol,2003,5(Suppl.5):S28-S35 被引量:1
  • 9[7]Jolleys JV,Donovan JL Nanchahal K,et al.Urinary symptoms in the community:how bothersome are they? Br J Urol,1994,74(5):551-555 被引量:1
  • 10[8]Kaplan SA,Rochrborn CG,Rovner ES,et al.Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder.a randomized controlled trial.JA-MA,2006,296(19):2319-2328 被引量:1

共引文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部